Detection of myeloma progression (PD) relies on serial 24-h urinary M protein measurements in patients without measurable serum M spike. We examined whether serial difference free light chain (dFLC) levels could be used as a surrogate for serial 24-h urine M protein measurements in monitoring for PD in patients with baseline measurable urine M protein. We studied 122 patients who had serial measurement of urine M protein and serum FLC and had demonstrated PD. The median increase in dFLC with progression as defined by urine M spike was 110% (IQR: 55-312) and median absolute increase was 74 mg/dL; while 89% of patients had dFLC increase ≥ 25%, 94% had absolute increase in dFLC > 10 mg/dL, and 98% met at least 1 of these 2 criteria at PD. In patients with baseline measurable serum FLC (n = 118), 89% had increase in dFLC ≥ 25%, 97% had dFLC increase of > 10 mg/dL, and 98% had 1 of the 2. We conclude that serial dFLC assessments can be used in place of serial 24-h urine protein assessments during myeloma surveillance to monitor for PD. Once patients have an absolute increase in dFLC of >10 mg/dL from the nadir, a 24-h urine collection can then be assessed to document PD as per the International Myeloma Working Group criteria.
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| INTRODUCTION
The American Cancer Society predicts 30 770 new cases of multiple myeloma (MM) will be diagnosed in 2018 with an individual lifetime risk of 1 in 143 or 0.7% with an incidence pattern that is increasing. 1 The initial work-up in the diagnosis of MM includes measurement of the monoclonal protein (M protein) in the serum or urine, which can be used as a marker to monitor disease activity and response to treatment. [2] [3] [4] A study at Mayo Clinic looking at 1027 newly diagnosed MM cases found that 93% of patients had M protein detected in the serum, 78% had urinary M protein, 20% had light-chain myeloma, and 3% had nonsecretory myeloma. 
| PATIENTS AND METHODS
The study population consisted of patients enrolled in clinical trials We further stratified our overall cohort into 2 additional groups:
those with baseline dFLC (≥10 mg/dL with an abnormal ratio at cycle 0 of therapy) and those with baseline dFLC plus 2 or more consecutive 24-h UPEP measurements meeting criteria for PD (defined as confirmed PD). First, urinary M protein, serum protein electrophoresis, and dFLC levels at sequential cycles of therapy were abstracted until patients met criteria for PD based on their urinary M protein values.
At PD, the dFLC medians and respective interquartile ranges were calculated from both absolute and percentage value increases from the nadir. The number of patients who met absolute and percentage dFLC thresholds of >10 mg/dL and ≥ 25% increase from the nadir respectively, were calculated in each group.
Finally, we assessed how much earlier PD could be detected using dFLC compared with 24-h urine protein values. This was accomplished by assigning cycle number zero to the time point when PD was detected with 24-h urine protein assessment and therefore cycles >0 corresponding to the number of cycles PD was detected earlier than that with UPEP.
| RESULTS
We Table 1 .
The number of patients who met both dFLC absolute and percentage value thresholds at or prior to PD was 105 of the 122 patients analyzed while 14 patients met either absolute or percent thresholds, and 3 patients did not meet either criterion. The cut-off values for dFLC were chosen based on current IMWG criteria for assessment of PD in light-chain myeloma (>10 mg/dL and ≥ 25% from the nadir). 3 We also looked at the kinetics of the 2 measures in defining pro- 
| DISCUSSION
Given the ability to measure the FLC levels in the serum, which reflects the light chains available for urinary excretion, we asked if serial measurements of sFLC will allow us to reduce the need for repeated 24-h urine examination during disease surveillance. We emphasize that our aim was not to suggest replacement of the 24-h urine protein assay in confirming PD or change the current response criteria, but to identify the degree of sFLC changes suggestive of PD that would trigger for assessment of 24-h urine.
When comparing the dFLC absolute and percentage PD thresholds with each other, more patients met criteria for the absolute increase in FLC levels. This was observed consistently in all 3 groups and appeared greatest in those with measurable baseline dFLC, with 97% fulfilling this criterion, supporting the use of serial FLC as a valid method to determine the timing of the 24-h urine examination. This finding is most likely due to the fact that absolute rather than percent change is correlated to a greater degree with quantification of urine protein and FLC absolute levels.
Our results also demonstrated that when applying dFLC cut-off values in predicting detection of PD earlier than UPEP, close to half of those patients (46%) met these thresholds at least 1 or more cycles ahead of when their 24-h urine protein studies did. This suggests that not only can serial sFLC levels be used in place of serial 24-h UPEP to detect PD, but may have a role in earlier detection. In fact, there were several cases in which PD using dFLC was detected 6-20 cycles ahead of detection with UPEP. This observation could be secondary to the fact that the 24-h urine protein assessment involves more steps and relies heavily on the accuracy of collection and is influenced by renal function, thereby possibly leading to greater variability whereas dFLC assessment is not dependent on these variables. However, the majority of patients (82%) met dFLC PD criteria within 2 cycles of detection with 24-h UPEP, further supporting its ability to not only detect progression, but its correlation in timing with 24-h urine protein assessment. It is unclear if the earlier detection and treatment will change outcomes.
One of the limitations of our study is that while all patients met IMWG 24-h urine protein cut-off thresholds for PD, the majority of these were based on 1 measurement as opposed to 2 consecutive samples, qualifying as unconfirmed PD. Because the aim of our analysis was to suggest using dFLC during disease surveillance during detection of PD rather than confirming PD, we did not feel that this had any significant impact on the quality of our study or its findings.
We conclude that among patients with measurable sFLC at baseline, dFLC assessments can be performed in place of serial 24-h urine protein assessments during myeloma surveillance to monitor for disease activity and detection of PD, and thereby flagging a critical time point in the disease course for which to obtain a 24-h urine protein assay to confirm PD. Specifically, once these patients have an increase in dFLC of >10 mg/dL from the nadir, a 24-h urine collection can then be assessed for M protein to evaluate for and confirm PD, reducing the burden of repetitive 24-h urine collections and leading to ease of testing.
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